DAVITA INC. Business Acquisition, Pro Forma Net Income (Loss)
DAVITA INC. (DVA) reported Business Acquisition, Pro Forma Net Income (Loss) of $727.21 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss · last filed 2026-02-11
- DAVITA INC. business acquisition, pro forma net income (loss) for the quarter ending 2017-12-31 was $562.04M, a 73.50% increase year-over-year.
- DAVITA INC. business acquisition, pro forma net income (loss) for the quarter ending 2017-09-30 was -$214.16M, a 137.38% decline year-over-year.
- DAVITA INC. business acquisition, pro forma net income (loss) for the quarter ending 2017-06-30 was $128.65M, a 118.07% increase year-over-year.
- DAVITA INC. business acquisition, pro forma net income (loss) for the quarter ending 2016-12-31 was $323.94M.
- DAVITA INC. business acquisition, pro forma net income (loss) for fiscal 2025 was $727.21M, a 25.00% decline from fiscal 2024.
- DAVITA INC. business acquisition, pro forma net income (loss) for fiscal 2024 was $969.66M, a 32.42% increase from fiscal 2023.
- DAVITA INC. business acquisition, pro forma net income (loss) for fiscal 2023 was $732.26M, a 33.08% increase from fiscal 2022.
- DAVITA INC. business acquisition, pro forma net income (loss) for fiscal 2022 was $550.25M, a 44.09% decline from fiscal 2021.
| Period end | Business Acquisition, Pro Forma Net Income (Loss) 3 month | Business Acquisition, Pro Forma Net Income (Loss) 3 month as first filed | Business Acquisition, Pro Forma Net Income (Loss) 6 month | Business Acquisition, Pro Forma Net Income (Loss) 6 month as first filed | Business Acquisition, Pro Forma Net Income (Loss) 9 month | Business Acquisition, Pro Forma Net Income (Loss) 9 month as first filed | Business Acquisition, Pro Forma Net Income (Loss) 12 month | Business Acquisition, Pro Forma Net Income (Loss) 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | $727.21M 10-K · filed 2026-02-11 | |||||||
| 2024-12-31 | $969.66M 10-K · filed 2026-02-11 | $952.84M 10-K · filed 2025-02-13 | ||||||
| 2023-12-31 | $732.26M 10-K · filed 2025-02-13 | $694.85M 10-K · filed 2024-02-14 | ||||||
| 2022-12-31 | $550.25M 10-K · filed 2024-02-14 | $545.86M 10-K · filed 2023-02-22 | ||||||
| 2021-12-31 | $984.23M 10-K · filed 2023-02-22 | $985.80M 10-K · filed 2022-02-11 | ||||||
| 2020-12-31 | $797.84M 10-K · filed 2022-02-11 | $789.47M 10-K · filed 2021-02-12 | ||||||
| 2019-12-31 | $718.93M 10-K · filed 2021-02-12 | $709.63M 10-K · filed 2020-02-21 | ||||||
| 2018-12-31 | $640.11M 10-K · filed 2020-02-21 | $634.33M 10-K · filed 2019-02-22 | ||||||
| 2017-12-31 | $562.04M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-22 | $347.88M derived: sum of 2 quarters · filed 2019-02-22 | $476.54M derived: sum of 3 quarters · filed 2019-02-22 | $922.72M 10-K · filed 2019-02-22 | $907.44M 10-K · filed 2018-02-23 | |||
| 2017-09-30 | -$214.16M 10-Q · filed 2017-11-07 | -$85.50M derived: sum of 2 quarters · filed 2017-11-07 | $360.68M 10-Q · filed 2017-11-07 | |||||
| 2017-06-30 | $128.65M 10-Q · filed 2017-08-01 | $579.91M 10-Q · filed 2017-08-01 | ||||||
| 2016-12-31 | $323.94M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-23 | $896.81M derived: sum of 2 quarters · filed 2018-02-23 | $955.81M derived: sum of 3 quarters · filed 2018-02-23 | $1.05B 10-K · filed 2018-02-23 | $884.28M 10-K · filed 2017-02-24 | |||
| 2016-09-30 | $572.87M 10-Q · filed 2017-11-07 | $571.53M 10-Q · filed 2016-11-02 | $631.87M derived: sum of 2 quarters · filed 2017-11-07 | $728.76M 10-Q · filed 2017-11-07 | $736.45M 10-Q · filed 2016-11-02 | $702.91M derived: sum of 4 quarters · filed 2017-11-07 | ||
| 2016-06-30 | $59.00M 10-Q · filed 2017-08-01 | $56.97M 10-Q · filed 2016-08-08 | $160.71M 10-Q · filed 2017-08-01 | $156.75M 10-Q · filed 2016-08-08 | $130.03M derived: sum of 3 quarters · filed 2017-08-01 | $354.84M derived: sum of 4 quarters · filed 2017-08-01 | ||
| 2016-03-31 | $97.01M 10-Q · filed 2016-05-04 | $71.04M derived: sum of 2 quarters · filed 2017-02-24 | $295.85M derived: sum of 3 quarters · filed 2017-02-24 | $468.40M derived: sum of 4 quarters · filed 2017-02-24 | ||||
| 2015-12-31 | -$25.97M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-24 | $198.84M derived: sum of 2 quarters · filed 2017-02-24 | $371.39M derived: sum of 3 quarters · filed 2017-02-24 | $280.12M 10-K · filed 2017-02-24 | $273.61M 10-K · filed 2016-02-26 | |||
| 2015-09-30 | $224.81M 10-Q · filed 2016-11-02 | $397.36M derived: sum of 2 quarters · filed 2016-11-02 | $306.10M 10-Q · filed 2016-11-02 | |||||
| 2015-06-30 | $172.55M 10-Q · filed 2016-08-08 | $64.90M 10-Q · filed 2016-08-08 | ||||||
| 2015-03-31 | -$109.03M 10-Q · filed 2016-05-04 | |||||||
| 2014-12-31 | $738.99M 10-K · filed 2016-02-26 | $733.49M 10-K · filed 2015-02-26 | ||||||
| 2013-12-31 | $651.20M 10-K · filed 2015-02-26 | $1.01B 10-K · filed 2014-02-21 | ||||||
| 2012-12-31 | $787.40M 10-K · filed 2014-02-21 | $775.26M 10-K · filed 2013-03-01 | ||||||
| 2011-12-31 | $463.22M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-01 | $818.66M 10-K · filed 2013-03-01 | $520.63M 10-K · filed 2012-02-24 | |||||
| 2011-09-30 | $355.44M 10-Q · filed 2011-11-04 | |||||||
| 2010-12-31 | $105.67M derived: 8-K 12 month − 10-Q 9 month · filed 2012-07-06 | $471.63M 8-K · filed 2012-07-06 | ||||||
| 2010-09-30 | $365.96M 10-Q · filed 2011-11-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sotera Health Co (SHC) | United States | $5.271B | 30.96 |
| Progyny, Inc. (PGNY) | United States | $1.994B | 28.37 |
| agilon health, inc. (AGL) | United States | $1.272B | -7.76 |
| VIEMED HEALTHCARE, INC. (VMD) | United States | $0.336B | 29.92 |
| Park Dental Partners, Inc. (PARK) | United States | $0.094B | |
| BioRestorative Therapies, Inc. (BRTX) | United States | $0.064B | |
| CRYO CELL INTERNATIONAL INC (CCEL) | United States | $0.033B | -11.02 |
| MANGOCEUTICALS, INC. (MGRX) | United States | $0.010B | -0.43 |